"With almost all provinces onboard, urgent medicines can now be more accessible to patients with diseases such as R/R DLBCL across the country," said Antonella Rizza, CEO, Lymphoma Canada.
The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult patients with diffuselargeB celllymphoma (DLBCL) and high-grade ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology ...